USPSTF 2022: aspirin use to prevent CVD

The 2022 recommendation statement issued by the US Preventive Services Task Force on taking low-dose aspirin to prevent cardiovascular disease in adults who do not already have it. Its advice differs by age: an individual decision for adults aged 40 to 59 at higher risk, and advice against starting at 60 or older. This statement updates its 2016 recommendation.

Also called Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement

Guideline
In this atlas

Overview

Technical summary

JAMA 2022;327(16):1577-1584, doi 10.1001/jama.2022.4983, PMID 35471505. The USPSTF page dates the final statement April 26, 2022. Only the PubMed abstract and that date line were read. Grades as the abstract labels them: C for adults aged 40 to 59 whose 10-year risk is 10% or more (an individual decision) and D for adults 60 or older (against starting). The abstract says the Task Force also commissioned a modelling study of net benefit by age, sex and risk level; its results were not read. The USPSTF permits reuse of its work only under its copyright notice, so this atlas states the recommendations in its own words, with a citation and a link.

About this guideline

Issued by: U.S. Preventive Services Task Force
Edition: 2022 recommendation statement
Published: 2022-04-26
Status: Not checked for a newer edition
Scope: Primary prevention of cardiovascular disease with low-dose aspirin in adults aged 40 or older without known cardiovascular disease and not at increased bleeding risk.

Source

Document: Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement
Publisher: JAMA
Edition note: Recommendation statement published in JAMA 2022;327(16):1577-1584. PubMed abstract and bibliographic data, plus the date line of the USPSTF recommendation page (both fetched 2026-10-15). The full statement, the evidence review, the modelling study and the Task Force grade definitions were not read. PubMed lists no correction to the statement.

Recommendations

Recommended against: Aspirin effective 2022-04-26

Record details

Record id: cardio:guideline-uspstf-2022-aspirin
Content hash: 186b8132ad56d452d30e936100cee65bd63ca6d52b5ac772b171ecfb36228681